EarningsKnight Therapeutics reported a strong quarterly performance, beating estimates and increasing its guidance.
Future Revenue GrowthKnight Therapeutics plans to launch over 10 new drugs, expected to significantly increase revenue and gross margin.
Product LaunchesThe specialty portfolio experienced significant growth, driven by successful launches of new products in Canada.